Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2

Conditions

Myelodysplastic Syndromes 361Leukemia, Myeloid, Acute 302Myeloproliferative Disorders 155Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Primary Myelofibrosis 103Leukemia, Myelomonocytic, Chronic 89Lymphoma, Non-Hodgkin 76Leukemia 71Polycythemia Vera 64Multiple Myeloma 55Hodgkin Disease 50Hematologic Neoplasms 49Leukemia, Lymphocytic, Chronic, B-Cell 44Leukemia, Biphenotypic, Acute 41Thrombocythemia, Essential 40Lymphoma 40Myelodysplastic-Myeloproliferative Diseases 32Neoplasms 29Leukemia, Myeloid, Chronic-Phase 28Anemia, Refractory, with Excess of Blasts 24Recurrence 23Anemia, Aplastic 21Lymphoma, Mantle-Cell 20Lymphoma, Follicular 20Hematologic Diseases 20Burkitt Lymphoma 20Blastic Plasmacytoid Dendritic Cell Neoplasm 20Blast Crisis 20Histiocytosis, Langerhans-Cell 19

Interventions

venetoclax 1ruxolitinib 1pevonedistat 1Imatinib Mesylate 1Dasatinib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × Myeloid × 1 year × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡